ContraFect to Present Company Overview, Including Clinical Plan for CF-301, at the 7th Annual Biotech Showcase January 7, 2015
ContraFect Receives FDA Approval to Initiate Clinical Trials of CF-301 for MRSA Bloodstream Infections December 22, 2014
ContraFect Corporation to Present at the Oppenheimer 25th Annual Healthcare Conference December 4, 2014
ContraFect and National Institute for Viral Disease Control and Prevention, China CDC Sign Agreement to Collaborate on Universal Influenza Treatment October 9, 2014